IDT, Illumina Partner on Data Analysis For Cancer Sequencing Workflows
The collaboration connects IDT's xGen FFPE and cfDNA sequencing library preparation workflows to Illumina's DRAGEN analysis platform.
Danaher subsidiary Integrated DNA Technologies (IDT) and Illumina have announced a collaboration to connect IDT’s xGen FFPE and cell-free DNA next-generation sequencing (NGS) library preparation workflows with Illumina’s DRAGEN secondary analysis platform, creating an end-to-end pipeline for somatic oncology research.
Illumina built a new application for IDT custom panels and includes a low-quality FFPE mode designed to extract variant data from degraded samples. Initial workflows focusing on FFPE samples are available now. A version optimized for cfDNA liquid biopsy targeted applications is slated for next year. Financial terms of the collaboration were not disclosed.
“This is a step toward reshaping how genomic data is generated, analyzed, and used in research,” Konstantin Fiedler, VP at IDT, said in a statement. “We’re building toward a future where more workflows are fully connected, highly performant, and built for real-world samples.”
The deal adds to already deep ties between the companies: IDT manufactures oligos used in Illumina’s sequencing-by-synthesis chemistry. While the current deal is centered on research-use library preparation workflows, earlier this year IDT launched its first in vitro diagnostic assays, the Archer FusionPlex-HT Dx and VariantPlex-HT Dx, both of which can use FFPE samples.
“Collaborations like this add a new way for people to enter Illumina’s insight ecosystem,” Kevin Moore, VP of software product management at Illumina, added.